3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Leukemia, Myeloid, Acute
2
Triple Negative Breast Neoplasms
1
Smoldering Multiple Myeloma
1
Sarcoma
1
Myelodysplastic Syndromes
1
Metastasis From Malignant Tumor of Kidney (Disorder)
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Cyclophosphamide
184
fludarabine phosphate
162
fludarabine
128
Busulfan
116
Tacrolimus
109
Mycophenolic Acid
101
Whole-Body Irradiation
97
Antilymphocyte Serum
87
Peripheral Blood Stem Cell Transplantation
84
Azacitidine
82
Melphalan
81
Filgrastim
74
Cytarabine
74
Cyclosporine
72
Methotrexate
64
Decitabine
57
Granulocyte Colony-Stimulating Factor
51
Thiotepa
45
Radiotherapy
41
thymoglobulin
40
Stem Cell Transplantation
40
Cord Blood Stem Cell Transplantation
40
venetoclax
39
Clofarabine
35
Sirolimus
30
Methylprednisolone
30
Specimen Handling
27
Etoposide
24
Alemtuzumab
24
Biopsy
23
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Myelodysplastic Syndromes
×
Immunotherapy, Active
×
Clear all
NCT01819558
2015-03-20
ALLO-WT1
Institut Paoli-Calmettes
Phase 1/2
Completed
2 enrolled